PropertyValue
?:abstract
  • This morning brought news from Moderna of the very first human results from trials of their closely-watched mRNA vaccine candidate (mRNA-1273) against the coronavirus Here’s Stat on the news, and here’s Endpts – the results can be summed up pretty quickly, because it’s all just at the press-release level to start with The trial was dosing volunteers in Phase I at three levels 25 micrograms, 100 micrograms, and 250 micrograms of the mRNA species First off, immunogenicity (whether or not these doses caused people to produce antibodies) The good news there is that every participant at every dose level began producing antibodies (in other words, they “seroconverted) by day 15 after the first injection The actual amount of antibodies produced went up in the higher-dosage group, and for the 25 and 100 µg folks, it went up after the second “booster” shot of mRNA as well (The high-dose 250 µg voluteers seem to have maxed out after the first shot, actually)
is ?:annotates of
?:creator
?:journal
  • Science
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • First Results from Moderna’s Coronavirus Vaccine
?:type
?:who_covidence_id
  • #291844
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/insmekv6>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/insmekv6>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all